Sichuan Biokin Pharmaceutical Co.,Ltd. (SHA:688506)
China · Delayed Price · Currency is CNY 266.84
-3.99 (-1.47%)
At close: Aug 31, 2026
SHA:688506 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 2,534 | 2,518 | 5,821 | 560.42 | 701.83 | 794.95 |
Other Revenue | 1.82 | 1.62 | 1.67 | 1.46 | 1.45 | 1.78 |
| 2,536 | 2,520 | 5,823 | 561.87 | 703.28 | 796.73 | |
Revenue Growth | 474.87% | -56.72% | 936.31% | -20.11% | -11.73% | -21.33% |
Cost of Revenue | 262.11 | 259.1 | 283.74 | 242.26 | 237.7 | 203.39 |
Gross Profit | 2,274 | 2,261 | 5,539 | 319.61 | 465.58 | 593.34 |
Selling, General & Admin | 553.45 | 547.33 | 405.04 | 367.89 | 403.01 | 467.46 |
Research & Development | 2,958 | 2,514 | 1,443 | 746.23 | 375.02 | 278.6 |
Other Operating Expenses | -4.56 | 2.3 | 4.24 | -2.27 | 9.79 | 9.17 |
Operating Expenses | 3,507 | 3,062 | 1,853 | 1,105 | 795.41 | 752.86 |
Operating Income | -1,233 | -800.69 | 3,686 | -785.6 | -329.83 | -159.52 |
Interest Expense | -106.22 | -85.07 | -42.52 | -24.68 | -22.48 | -8.69 |
Interest & Investment Income | 236.61 | 226.33 | 225.32 | 5.71 | 0.77 | 3.61 |
Currency Exchange Gain (Loss) | -326.45 | -97.74 | 63.88 | -1.11 | -0.05 | -0.14 |
Other Non Operating Income (Expenses) | -2.29 | 0.34 | -3.38 | -0.84 | -0.56 | -0.35 |
EBT Excluding Unusual Items | -1,431 | -756.81 | 3,930 | -806.51 | -352.16 | -165.09 |
Gain (Loss) on Sale of Investments | 136.77 | 4.17 | 11.44 | - | - | - |
Gain (Loss) on Sale of Assets | -10.42 | -3.33 | -0.22 | -0.14 | -0.48 | -0.45 |
Other Unusual Items | 33.42 | 34.53 | 37.3 | 37.64 | 63.57 | 61.1 |
Pretax Income | -1,271 | -721.43 | 3,978 | -769.01 | -289.07 | -104.44 |
Income Tax Expense | 301.79 | 332.18 | 270.65 | 11.49 | -6.69 | -4.45 |
Earnings From Continuing Operations | -1,573 | -1,054 | 3,708 | -780.5 | -282.38 | -99.99 |
Net Income | -1,573 | -1,054 | 3,708 | -780.5 | -282.38 | -99.99 |
Net Income to Common | -1,573 | -1,054 | 3,708 | -780.5 | -282.38 | -99.99 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 410 | 404 | 401 | 400 | 362 | 357 |
Shares Outstanding (Diluted) | 410 | 404 | 401 | 400 | 362 | 357 |
Shares Change | 2.20% | 0.72% | 0.14% | 10.56% | 1.38% | 3.64% |
EPS (Basic) | -3.84 | -2.61 | 9.25 | -1.95 | -0.78 | -0.28 |
EPS (Diluted) | -3.84 | -2.61 | 9.25 | -1.95 | -0.78 | -0.28 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -1,588 | -1,062 | 3,975 | -697.29 | -293.21 | -179.63 |
Free Cash Flow Per Share | -3.88 | -2.63 | 9.92 | -1.74 | -0.81 | -0.50 |
Gross Margin | 89.66% | 89.72% | 95.13% | 56.88% | 66.20% | 74.47% |
Operating Margin | -48.60% | -31.77% | 63.31% | -139.82% | -46.90% | -20.02% |
Profit Margin | -62.02% | -41.81% | 63.67% | -138.91% | -40.15% | -12.55% |
Free Cash Flow Margin | -62.62% | -42.15% | 68.26% | -124.10% | -41.69% | -22.55% |
EBITDA | -1,143 | -719.55 | 3,754 | -727.25 | -272.27 | -109.37 |
EBITDA Margin | -45.07% | -28.55% | 64.48% | -129.43% | -38.71% | -13.73% |
D&A For EBITDA | 89.41 | 81.14 | 68.03 | 58.34 | 57.56 | 50.16 |
EBIT | -1,233 | -800.69 | 3,686 | -785.6 | -329.83 | -159.52 |
EBIT Margin | -48.59% | -31.77% | 63.31% | -139.82% | -46.90% | -20.02% |
Effective Tax Rate | - | - | 6.80% | - | - | - |
Revenue as Reported | 2,536 | 2,520 | 5,823 | 561.87 | 703.28 | 796.73 |